IP Library Granted Patent US 9,266,041
Granted Patent B2
US 9,266,041 · App. 13/158,780 · Granted Feb 23, 2016

Chromatography ligand

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,266,041
App. No.
13/158,780
Granted
Feb 23, 2016
Kind
B2
Abstract

The present invention relates to a chromatography ligand defined by the following formula R 1 —R 2 —N(R 3 )—R 4 —R 5 wherein R 1 is a substituted or non-substituted phenyl group; R 2 is a hydrocarbon chain comprising 0-4 carbon atoms; R 3 is a hydrocarbon chain comprising 1-3 carbon atoms; R 4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R 5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.

Claims (18)

1. A separation matrix comprising chromatography ligands immobilized to a membranous support, wherein the chromatography ligands are defined by the following formula

R 1 —R 2 —N(R 3 )—R 4 —R 5

wherein

R 1 is a substituted or non-substituted phenyl group;

R 2 is a hydrocarbon chain comprising 0-4 carbon atoms;

R 3 is a hydrocarbon chain comprising 1-3 carbon atoms;

R 4 is a hydrocarbon chain comprising 1-5 carbon atoms; and

R 5 is OH and wherein the chromatography ligands are immobilized to the membranous support via covalent coupling of the nitrogen atom of the tertiary amine of the ligand having the formula R 1 —R 2 —N(R 3 )—R 4 —R 5 to the membranous support such that the tertiary amine of the ligand is converted to a quaternary amine.

2. The separation matrix of claim 1 , wherein R 1 is a non-substituted phenyl group.

3. The separation matrix of claim 1 , wherein R 2 is —CH 2 —.

4. The separation matrix of claim 1 , wherein R 3 is —CH 3 .

5. The separation matrix of claim 1 , wherein R 4 is —CH 2 —CH 2 —CH 2 —or —CH 2 —CH 2 —.

6. The separation matrix of claim 1 , which comprises N-benzyl-N-methyl ethanol amine.

7. The separation matrix of claim 1 , wherein the ligands are immobilised via a linker.

8. The separation matrix of claim 1 , wherein the membranous support comprises a microfiltration membrane.

9. The separation matrix of claim 1 , wherein the membranous support comprises a cross-linked cellulose membrane.

10. The separation matrix of claim 1 , wherein the content of said ligands is at least 40 micromole/ml matrix, such as at least 200 micromole/ml matrix.

11. A method of manufacturing a filter, which method comprises providing the separation matrix of claim 1 ; arranging the matrix in a cartridge or capsule; and sterilizing the cartridge or capsule comprising the matrix.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2011
From: JOHANSSON, BO-LENNART; MALOISEL, JEAN-LUC; JOHANSSON, HANS J.; EK, ASA; HOLM, MARIA; SAIDZADEH, JAFAR
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 026614/0967 →